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This review will discuss the contributions of marine natural molecules, a source only recently found to have
pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds
with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded
valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity
and supply. In this context, the development of these compounds will be discussed herein to illustrate, with
successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved
in this process as well as the scientific advances and technological innovation potential associated with
developing a new drug from marine resources.
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lites Drugs; Anti-tubulin Drugs; DNA-Alkylating Agents.
’ INTRODUCTION
Cancer remains one of the major issues for public health
systems worldwide, and projections of the US National
Cancer Institute have indicated an increase of 50% in cancer
cases, reaching 21 million new cases in the next two decades
(1). According to these projections, 7 out of 10 deaths caused
by cancer will occur in Africa, Asia and Central and South
America (2), challenging countries such as Brazil to improve
strategies for surveillance, early diagnosis and effective treat-
ment of cancer patients.
The usual forms of cancer treatment include surgery,
radiotherapy and chemotherapy (3). Unlike surgery and
radiotherapy, which are methods primarily indicated for
solid tumors, chemotherapy is a form of systemic drug-based
treatment that interferes with the process of growth and
cell division in tumor cells. Currently, cancer chemotherapy
is facing a remarkable revolution with the introduction of
an increasing number of target-oriented drugs, increasing
treatment efficacy, reducing side effects and improving the
quality of life of patients (4).
However, despite the considerable arsenal of drugs avai-
lable for cancer chemotherapy and the therapeutic success of
various treatment regimens, existing therapies do not always
achieve the expected results, as tumor recurrence and the
onset of metastasis often occur (5,6). Therefore, the search for
more selective compounds with fewer side effects, greater
therapeutic potency and a lower resistance index for cancer
therapy is of paramount importance.
Natural products in cancer treatment
Natural products have made the greatest contribution to
the development of drugs in cancer chemotherapy as the
origin of over 70% of compounds in clinical use (7-9). Various
examples of antineoplastic analogs obtained from plants and
widely used therapeutically include vinblastine (Velbans),
vincristine (Oncovins) and their analogs vindesine (Eldi-
sines) and vinorelbine (Navelbines); paclitaxel (Taxols)
and the analogs docetaxel (Taxoteres) and cabazitaxel
(Jevtanas); podophyllotoxin and analogs etoposide (Eto-
pophoss), teniposide (Vumons) and belotecan (Campto-
bells); and camptothecin and analogs topotecan (Hycamtins)
and irinotecan (Camptosars). Soil bacteria are also a notable
source of anticancer drugs, which can be clearly illus-
trated by compounds such as the anthracyclines doxorubi-
cin (Doxils; Adriamycins), daunorubicin (Cerubidines)
and epirubicin (Ellences); the glycopeptide bleomycin
(Blenoxanes); and the non-ribosomal peptide dactinomycin
(Cosmegens) (9-11).
The compact and peculiar arrangement of natural mole-
cules contains structural requirements that allow binding
to specific targets or molecular interactions, resulting in
phenotypic changes in biological systems (12-14). These pro-
perties are closely related to their pharmacological potential
and therapeutic success in the most diverse diseases. There
are estimates that 64% of all drugs currently registered have
a natural product involved in their development (15,16).DOI: 10.6061/clinics/2018/e482s
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There is extraordinary potential for the discovery of new
naturally occurring anticancer drugs due to their invaluable
biological diversity. To date, it has been estimated that less
than 2% of plants have been analyzed for antineoplastic con-
stituents, and even then, only cytotoxic activity was sought.
In fact, a large number of molecules with antineoplastic acti-
vity derived from marine organisms, microorganisms and
plants can still be revealed, and in addition, many known
substances show unprecedented activities when tested against
new therapeutic targets (10,17).
Innovation from the sea
Seven marine-based pharmaceuticals have been approved
for marketing, 23 compounds are in clinical trials between
phases I and III, and over one thousand compounds isolated
from marine organisms are undergoing preclinical studies
(18-21). It should be noted that among those marine organism-
derived compounds in clinical use, four are used in the
treatment of cancer: cytarabine (Cytosars), trabectedin
(Yondeliss), eribulin mesylate (Halavens) and the conju-
gated antibody brentuximab vedotin (Acentriss). Herein, we
will discuss relevant elements of the four approved anticancer
drugs, emphasizing the knowledge to overcome obstacles that
make the process of natural product drug research and
development an expensive, laborious and time-consuming
endeavor.
Cytarabine (Cytosar) – Debuting marine compounds
in the cancer field
Werner Bergmann from Yale University and a group of
collaborators throughout the 1940s and 1950s published
several articles in a series they called ‘‘contributions to the
study of marine products’’ (22-26). The most significant of
these works was the isolation of the arabinonucleosides
spongothymidine and spongouridine (Figure 1) from the
Caribbean sponge Cryptotethya crypta (now renamed Tecti-
tethya crypta) (23). The discovery of these nucleosides was
further entwined with two important scientific develop-
ments: the first was breaking the existing paradigm that a
nucleoside would have biological function only if it had
ribose or deoxyribose in its structure; and the second was
the introduction of the pharmacological concept of anti-
metabolites in the context of anticancer chemotherapy,
with the synthesis of analogs of natural arabinonucleosides
and cytosine arabinose and the development of cytarabine
(or Ara-C).
An antimetabolite drug is one that has a structure suf-
ficiently similar to that of a metabolite produced naturally by
the body such that it could be recognized but lacks the ability
to preserve its function, thereby interfering with normal
cell metabolism (27). In this context, similar to that of its
natural prototypes, the mechanism of action of cytarabine is
based on its rapid conversion to the respective triphosphate
arabinonucleoside through sequential phosphorylation. The
triphosphocytarabine then becomes a DNA polymerase sub-
strate and is subsequently incorporated into the DNA in
place of a cytosine. However, due to the presence of arabi-
nose in place of deoxyribose, the cytarabine triphosphate,
once bound to DNA, prevents the formation of a phospho-
diester bond between the two pentoses and, therefore, the
elongation of the DNA strain, thus interrupting the process
of DNA synthesis (28,29) (Figure 1).
Cytarabine was approved for clinical use in 1969 and is
still widely used in the treatment of various types of leukemia,
such as acute lymphocytic leukemia, acute myelogenous
leukemia, chronic myelogenous leukemia, and non-Hodgkin’s
lymphoma. Although this molecule is a synthetic analog
and not the natural product itself, cytarabine is historically
Figure 1 - Chemical structures of cytarabine and related natural products, spongothymidine and spongouridine, isolated from the
marine sponge Tectitethya cripta (top). A schematic representation of the mechanism of action of cytarabine in cancer cells (bottom).
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reported as the first example of a commercially available
marine-derived drug.
However, it is important to emphasize that the principle
of using a nonfunctional nucleoside to inhibit the elonga-
tion of the DNA strand, which was first observed with
the arabinonucleosides of C. crypta, is a strategy used in other
chemotherapeutic treatments. Another of these analogs,
adenine arabinose, has been developed into the antiviral
drug vidarabine (or Ara-A), which has been clinically used
since 1976 for the treatment of Herpes simplex and Varicella
zoster, among other viral infections. Furthermore, the antiviral
azidothymidine (AZT or zidovudine), the first available
treatment for AIDS and part of the WHO model list of
essential drugs, deserves attention. This molecule, a thymidine
analog in which the pentose is linked to an N chain, was
synthesized in 1964 with anticancer claims that it did not
fulfill. However, when the spread of AIDS rapidly turned into
an epidemic in the mid-1980s, in the search for an anti-HIV
compound, AZT proved to be extremely effective in blocking
the viral reverse transcriptase enzyme, which is crucial for
HIV retrovirus replication (30).
Trabectedin (Yondeliss) – Overcoming the
supply problem
The anticancer activity of extracts obtained from the
Caribbean ascidian Ecteinascidia turbinata has been known
since the 1960s (31), but the isolation and structural eluci-
dation of its active principle occurred more than 20 years
later, as described by Rinehart et al. (32) and Wright et al.
(33). ET-743, also called ecteinascidin 743 or trabectedin
(Figure 2), was identified as the most abundant of the six
structurally related alkaloids produced by ascidian.
Mode of action studies recognized this molecule as a DNA
alkylator with a mechanism that differs from that of most
typical alkylating agents (Figure 2). Trabectedin binds to
guanine residues arranged in specific sequences in the minor
groves of the double-helix, further bending DNA strands
toward the opposite side of the alkylation site (34,35). These
adducts created by trabectedin prevent DNA transcrip-
tion by arresting RNA polymerase II activity (36-38). Inhibi-
tion of MDR1 gene transcription is one of the most relevant
effects, as this gene is responsible for the production of
P-glycoprotein, which participates in the cellular detoxification
process (39,40). Additionally, the transcription and consequent
production of chaperones, such as heat shock proteins (HSPs),
are also affected (41,42). The TC-NER pathway (repair by
nucleotide excision coupled to transcription), which is recrui-
ted after RNA polymerase II arrest to repair DNA lesions
detected during the transcription process, also appears to be
compromised by trabectedin. Moreover, it has been shown
that TC-NER-deficient cells are resistant to the effect of this
compound (35,36).
Also worthy of mention are the recent findings on the
effects of trabectedin on the tumor microenvironment (TME).
The TME contains nontumor cells, such as macrophages,
which actively communicate with tumor cells. These macro-
phages release inflammatory mediators as well as growth
and angiogenic factors that enable the proliferation and meta-
stasis of tumor cells. While TME cells are normally quiescent
and have low sensitivity to most chemotherapy treatments,
trabectedin has been shown to reduce the tumor inflammatory
response in addition to activating caspase 8 and selectively
inducing apoptosis in monocytes and macrophages (43).
Trabectedin was obtained by total synthesis for the first
time in 1996 using an extremely complex process with low
Figure 2 - Chemical structures of trabectedin isolated from the ascidian Ecteinascidia turbinata and its precursor cyanosafracin
B isolated from the bacteria Pseudomonas fluorescens (top). A schematic representation of the mechanism of action of trabectedin in
cancer cells (bottom).
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yield of the final product (44). Years later, the same group
was able to simplify the process and improve compound
yield; however, the chemical synthesis did not prove to be
effective in providing trabectedin in sufficient quantities to
meet the demands of the clinic. Cultivation of the ascidian in
marine farms (or mariculture) was also considered an option
to address issues related to the supply of the molecule. How-
ever, the production of trabectedin in cultivated Ecteinascidia
turbinata was inconsistent and generally reduced when com-
pared to that in organisms found under natural ecological
circumstances, as 1 ton of cultivated ascidian was sufficient
for the isolation of merely 1 g of the molecule (45). The supply
of trabectedin to ensure commercialization of the product and
its clinical use resulted in the development of a semisynthe-
tic process from the intermediate cyanosafracin B, a large-
scale antibiotic obtained from the bacterium Pseudomonas
fluorescens (46).
Trabectedin, under the trademark Yondeliss, was devel-
oped by PharmaMar, a pharmaceutical company dedica-
ted exclusively to research and development of drugs from
marine organisms. Notably, this was the first marine natural
molecule approved for clinical use in cancer chemotherapy
and was the first drug in 20 years to be validated for the
treatment of soft tissue sarcoma. Yondeliss received author-
ization from the European Medicines Agency (EMEA) for
marketing in 2007. The FDA, however, approved the use
of Yondeliss only in 2015.
Eribulin Mesylate (Halaven) – Understanding
structure-activity relationships
Halichondrins are a series of macrocyclic polyethers with
pronounced anticancer activity both in vitro and in vivo that
were isolated by Hirata and Uemura (47) from the sponge
Halichondria okadai collected on the coast of Japan at the
Miura Peninsula. Among them, halichondrin B (Figure 3),
a compound with high molecular weight (approximately
1,110 g/mol), served as a prototype for eribulin, an analog in
the form of a mesylate salt (Figure 3).
The route of total synthesis of halichondrin B was determi-
ned by Aicher et al. (48). In addition, studies of the relationship
between structure and biological activity demonstrated that it
was the macrocyclic ring and not the side chain that afforded
anticancer activity to this molecule (49). Thus, eribulin mesy-
late, which has maintained almost only the macrocyclic ring,
nearly halving its molecular weight (to 729.90 g/mol), is to date
the most complex drug obtained by total synthesis (49).
Eribulin mesylate, a derivative of the natural molecule,
is a potent antimitotic compound that acts as an inhibitor
of microtubule dynamics with an in vitro IC50 in the low
nM range. The specific target of this compound is tubulin,
whereby binding to specific regions prevent polymeriza-
tion and, consequently, arrest the extension of microtubules
(Figure 3). By these means, the cell remains in an irreversible
mitosis blockage, and the prolongation of this state finally
leads to death by apoptosis (50). Eribulin was developed by
Eisai, a Japanese-based pharmaceutical company that has a
research operation in the USA, with considerable support
from the National Cancer Institute (NCI) during this process.
In 2010, Halavens, or eribulin mesylate, was approved by
the FDA to treat advanced metastatic breast cancer, and in
2016, it became the second line of treatment for liposarcoma
therapy (21).
Brentuximab vedotin (Adcetris) – Targeted
cytotoxic drugs
In 1972, extracts obtained from the gastropod mollusk
Dolabella auricularia, which is found in the Indian Ocean, stood
out for their pronounced anticancer activity. Nevertheless,
Figure 3 - Chemical structures of eribulin mesylate and the related natural product halichondrin B isolated from the sponge
Halichondria okadai (top). A schematic representation of the mechanism of action of eribulin mesylate in cancer cells (bottom).
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only 15 years later, the peptides called dolastatins were
identified as the active compounds of these extracts, among
which dolastatins 10 and 15 exhibited potent antiprolifera-
tive activities against several tumor cell lines (51). Tubulin
was also established as the main target of action of these
peptides; therefore, the blockade of microtubule polymer-
ization and, consequently, cell division is the mechanism by
which dolastatins inhibit the proliferation of tumor cells (52).
Despite the extraordinary in vitro activity of dolastatins –
dolastatin 10 demonstrated IC50 in the order of pM against
a panel of tumor cells – none of these peptides, nor their
synthetic derivatives, such as auristatin (soblidotin), cema-
todine, and syntatodine, progressed beyond phase II in clinical
trials (53,54). However, monomethylauristatin E (MMAE or
vedotin), a derivative of auristatin, successfully became the
warhead of the antibody-drug complex (ADC) brentuximab
vedotin (Figure 4) developed by the US-based company Seattle
Genetics and known commercially as Adcetriss (55,56). ADCs
are composed of a monoclonal antibody covalently linked to
the pharmacological agent (57). In the specific case of bren-
tuximab vedotin, the antibody is directed against CD30,
a membrane protein recognized as a tumor marker for some
types of lymphomas. Thus, vedotin selectively targets cells
expressing CD30, and some types of tumor cells do so in
greater amounts. Recognition of the brentuximab antibody
by the CD30 protein leads to the internalization of the ADC,
and within the cell, proteolytic cleavage releases vedotin
from the complex. In turn, free vedotin reaches its target of
action, blocking cell division and, ultimately, inducing cell
death (56) (Figure 4).
Adcetriss was approved in 2012 for the treatment of
Hodgkin’s lymphoma, a type of cancer that is distinguished
by the high expression of CD30. MMAE has also been
included in the formation of other ADCs that are currently
undergoing clinical trials, with the antibody of the complex
directed to different membrane proteins. Glembatumumab
vedotin (CDX-011) recognizes cells with NBM transmem-
brane glycoprotein expression and is being tested in patients
with advanced melanoma as well as those with metastatic
breast cancer. Pinatuzumab vedotin and polatuzumab vedo-
tin, which are antibodies directed at CD22 and CD79b
proteins, respectively, are being tested for the treatment of
leukemias and lymphomas (58).
In Brazil, the bioprospection of marine organisms with
biomedical properties is rapidly expanding but falls short
when considering the richness of the biodiversity among
the diverse ecosystems of coast and islands. During the last
decade, substantial effects of this expansion can be con-
firmed, such as increased scientific production, structuring of
research networks, training of human resources and deposits
of patents. Our research group has focused on the isolation of
biologically relevant molecules from invertebrates from the
Brazilian coast for the past 17 years (59-62). Lately, to pursue
sustainability and broaden the bioprospective regions, the
group has begun to examine marine bacteria, including both
free-living and invertebrate endophytes, for their antican-
cer potential (63-67). Microorganism collection and isolation
efforts from diverse matrixes and localities, ranging from
the coast to remote islands, have led to a current in-house
bank of over 1,000 bacterial strains. This collection has been
screened for cytotoxicity against tumor cells, and some strains
have been further evaluated in other contexts, either chemical
or biological, using the traditional phenotypic approach or a
target-oriented strategy.
Nevertheless, ventures in this area are essentially academic
and, consistent with the bioprospection of medicinal plants,
Figure 4 - Structure of brentuximab vedotin, an antibody-drug conjugate developed with the active principle monomethylauristatin E,
a derivative of the natural product dolastatin 10 isolated from the mollusk Dolabella auricularia (top). A schematic representation of
the mechanism of action of brentuximab vedotin in cancer cells expressing the CD30 antigen on the membrane (bottom).
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are considerably more widespread in the country; there is
a dissonance with the industrial sector, thus allowing the
underutilization of the biological resource. Nevertheless, Brazil
has been identified by Conservation International as a mega-
diverse country, a title backed by the large share of biological
diversity housed within our territorial boundaries that is
shared with only 16 other nations. In this sense, these yet
subproductive salty waters that bathe our coast are expected
to shelter quite a generous pharmacological potential.
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